Literature DB >> 26813801

Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11.

Mark G Thompson1, Allison Naleway2, Alicia M Fry3, Sarah Ball4, Sarah M Spencer3, Sue Reynolds3, Sam Bozeman2, Min Levine3, Jacqueline M Katz3, Manjusha Gaglani5.   

Abstract

BACKGROUND: Recently, lower estimates of influenza vaccine effectiveness (VE) against A(H3N2) virus illness among those vaccinated during the previous season or multiple seasons have been reported; however, it is unclear whether these effects are due to differences in immunogenicity.
METHODS: We performed hemagglutination inhibition antibody (HI) assays on serum collected at preseason, ∼ 30 days post-vaccination, and postseason from a prospective cohort of healthcare personnel (HCP). Eligible participants had medical and vaccination records for at least four years (since July, 2006), including 578 HCP who received 2010-11 trivalent inactivated influenza vaccine [IIV3, containing A/Perth/16/2009-like A(H3N2)] and 209 HCP who declined vaccination. Estimates of the percentage with high titers (≥ 40 and>100) and geometric mean fold change ratios (GMRs) to A/Perth/16/2009-like virus by number of prior vaccinations were adjusted for age, sex, race, education, household size, hospital care responsibilities, and study site.
RESULTS: Post-vaccination GMRs were inversely associated with the number of prior vaccinations, increasing from 2.3 among those with 4 prior vaccinations to 6.2 among HCP with zero prior vaccinations (F[4,567]=9.97, p<.0005). Thirty-two percent of HCP with 1 prior vaccination achieved titers >100 compared to only 11% of HCP with 4 prior vaccinations (adjusted odds ratio=6.8, 95% CI=3.1 - 15.3).
CONCLUSION: Our findings point to an exposure-response association between repeated IIV3 vaccination and HI for A(H3N2) and are consistent with recent VE observations. Ultimately, better vaccines and vaccine strategies may be needed in order to optimize immunogenicity and VE for HCP and other repeated vaccinees. Published by Elsevier Ltd.

Entities:  

Keywords:  healthcare personnel; hemagglutination inhibition antibody; immunogenicity; influenza vaccination

Mesh:

Substances:

Year:  2016        PMID: 26813801      PMCID: PMC5218812          DOI: 10.1016/j.vaccine.2015.10.119

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  36 in total

1.  Variable efficacy of repeated annual influenza vaccination.

Authors:  D J Smith; S Forrest; D H Ackley; A S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response.

Authors:  Zhongying Chen; Helen Zhou; Hong Jin
Journal:  Vaccine       Date:  2010-05-28       Impact factor: 3.641

3.  Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence.

Authors:  Joon Young Song; Hee Jin Cheong; In Sook Hwang; Won Suk Choi; Yu Mi Jo; Dae Won Park; Geum Joo Cho; Taik Gun Hwang; Woo Joo Kim
Journal:  Vaccine       Date:  2010-04-13       Impact factor: 3.641

4.  Stratified estimates of influenza vaccine effectiveness by prior vaccination: caution required.

Authors:  Sheena G Sullivan; Heath Kelly
Journal:  Clin Infect Dis       Date:  2013-04-25       Impact factor: 9.079

Review 5.  Regulatory effect of antibody on the immune response.

Authors:  J W Uhr; G Möller
Journal:  Adv Immunol       Date:  1968       Impact factor: 3.543

6.  Estimates of deaths associated with seasonal influenza --- United States, 1976-2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-08-27       Impact factor: 17.586

7.  Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010-2011 and 2011-2012 influenza seasons.

Authors:  Mark G Thompson; De-Kun Li; Pat Shifflett; Leslie Z Sokolow; Jeannette R Ferber; Samantha Kurosky; Sam Bozeman; Sue B Reynolds; Roxana Odouli; Michelle L Henninger; Tia L Kauffman; Lyndsay A Avalos; Sarah Ball; Jennifer L Williams; Stephanie A Irving; David K Shay; Allison L Naleway
Journal:  Clin Infect Dis       Date:  2013-11-26       Impact factor: 9.079

8.  Evidence for antigenic seniority in influenza A (H3N2) antibody responses in southern China.

Authors:  Justin Lessler; Steven Riley; Jonathan M Read; Shuying Wang; Huachen Zhu; Gavin J D Smith; Yi Guan; Chao Qiang Jiang; Derek A T Cummings
Journal:  PLoS Pathog       Date:  2012-07-19       Impact factor: 6.823

9.  The role of social contacts and original antigenic sin in shaping the age pattern of immunity to seasonal influenza.

Authors:  Adam J Kucharski; Julia R Gog
Journal:  PLoS Comput Biol       Date:  2012-10-25       Impact factor: 4.475

10.  Influence of prior influenza vaccination on antibody and B-cell responses.

Authors:  Sanae Sasaki; Xiao-Song He; Tyson H Holmes; Cornelia L Dekker; George W Kemble; Ann M Arvin; Harry B Greenberg
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

View more
  38 in total

Review 1.  Immune history and influenza virus susceptibility.

Authors:  Sarah Cobey; Scott E Hensley
Journal:  Curr Opin Virol       Date:  2017-01-12       Impact factor: 7.090

2.  Preexisting Immunity, Not Frailty Phenotype, Predicts Influenza Postvaccination Titers among Older Veterans.

Authors:  Puja Van Epps; Terrence Tumpey; Melissa B Pearce; Hana Golding; Patricia Higgins; Thomas Hornick; Christopher Burant; Brigid M Wilson; Richard Banks; Stefan Gravenstein; David H Canaday
Journal:  Clin Vaccine Immunol       Date:  2017-03-06

Review 3.  Factors affecting immune responses to the influenza vaccine.

Authors:  Maria R Castrucci
Journal:  Hum Vaccin Immunother       Date:  2017-07-21       Impact factor: 3.452

4.  Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010-2011 to 2014-2015.

Authors:  Danuta M Skowronski; Catharine Chambers; Gaston De Serres; Suzana Sabaiduc; Anne-Luise Winter; James A Dickinson; Jonathan B Gubbay; Kevin Fonseca; Steven J Drews; Hugues Charest; Christine Martineau; Mel Krajden; Martin Petric; Nathalie Bastien; Yan Li; Derek J Smith
Journal:  J Infect Dis       Date:  2017-04-01       Impact factor: 5.226

5.  Impact of Repeated Influenza Immunization on Respiratory Illness in Children With Preexisting Medical Conditions.

Authors:  Marieke L A de Hoog; Roderick P Venekamp; Roger A M J Damoiseaux; Anne G M Schilder; Elisabeth A M Sanders; Henriette A Smit; Patricia C J L Bruijning-Verhagen
Journal:  Ann Fam Med       Date:  2019-01       Impact factor: 5.166

6.  The Effectiveness of Trivalent Inactivated Influenza Vaccine in Children with Acute Leukemia.

Authors:  April Sykes; Elsie Gerhardt; Li Tang; Elisabeth E Adderson
Journal:  J Pediatr       Date:  2017-12       Impact factor: 4.406

7.  Impact of seasonal influenza vaccination in the presence of vaccine interference.

Authors:  Eunha Shim; Kenneth J Smith; Mary Patricia Nowalk; Jonathan M Raviotta; Shawn T Brown; Jay DePasse; Richard K Zimmerman
Journal:  Vaccine       Date:  2018-01-09       Impact factor: 3.641

Review 8.  Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies.

Authors:  Marc Rondy; Nathalie El Omeiri; Mark G Thompson; Alain Levêque; Alain Moren; Sheena G Sullivan
Journal:  J Infect       Date:  2017-09-18       Impact factor: 6.072

Review 9.  Challenges of Making Effective Influenza Vaccines.

Authors:  Sigrid Gouma; Elizabeth M Anderson; Scott E Hensley
Journal:  Annu Rev Virol       Date:  2020-05-11       Impact factor: 10.431

10.  Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines During the 2017-2018 Season.

Authors:  Sigrid Gouma; Seth J Zost; Kaela Parkhouse; Angela Branche; David J Topham; Sarah Cobey; Scott E Hensley
Journal:  Clin Infect Dis       Date:  2020-09-12       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.